Literature DB >> 22565125

Evolution of hemangioma endothelium.

Alexandra Kleiman1, Emily C Keats, Nancy G Chan, Zia A Khan.   

Abstract

Infantile hemangioma is a benign vascular tumor, characterized by a unique life cycle consisting of rapid growth and spontaneous regression. Three distinct phases (proliferating, involuting, and involuted) take place over the course of approximately 5-8 years, with specific cell types defining each separate phase. The origin of the cells comprising hemangiomas has been deliberated over since the late 1800s. We have recently provided experimental evidence that hemangiomas arise from multipotent stem cells. These hemangioma stem cells that give rise to the endothelial cells are also the essential source of adipocytes during hemangioma involution. The molecular mechanisms that regulate the differentiation of the hemangioma stem cells remain unclear. Although recent studies have elucidated a number of signaling pathways underlying hemangioma pathogenesis, many unanswered questions remain. Herein, we review the unique cellular composition of infantile hemangioma, as well as some of the signaling pathways active within hemangioma-genesis. Understanding the mechanisms behind changes in cellular fate throughout the hemangioma growth pattern will not only provide insight into the stem cell population that resides within the tumor, but will help to establish more effective eradicating therapies.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22565125     DOI: 10.1016/j.yexmp.2012.04.020

Source DB:  PubMed          Journal:  Exp Mol Pathol        ISSN: 0014-4800            Impact factor:   3.362


  14 in total

1.  Infant skin maturation: Preliminary outcomes for color and biomechanical properties.

Authors:  M O Visscher; S A Burkes; D M Adams; A M Hammill; R R Wickett
Journal:  Skin Res Technol       Date:  2017-03-16       Impact factor: 2.365

2.  Elevated T-box 2 in infantile hemangioma stem cells maintains an adipogenic differentiation-competent state.

Authors:  Sydney M Todorovich; Zia A Khan
Journal:  Dermatoendocrinol       Date:  2013-11-05

3.  Bilateral congenital infantile hemangioma of upper eyelids.

Authors:  Syed Ali Raza Rizvi; Faizan Mehmood; Abhishek Agrawal
Journal:  Indian J Ophthalmol       Date:  2016-04       Impact factor: 1.848

4.  Comparative Analysis of the Extracellular Matrix Composition in Proliferating and Involuted Infantile Hemangiomas.

Authors:  Hyochun Park; Hannara Park; Ho Yun Chung; Teresa M O; Milton Waner
Journal:  Arch Plast Surg       Date:  2015-09-15

Review 5.  Biology of infantile hemangioma.

Authors:  Tinte Itinteang; Aaron H J Withers; Paul F Davis; Swee T Tan
Journal:  Front Surg       Date:  2014-09-25

6.  Infantile Hemangioma Originates From A Dysregulated But Not Fully Transformed Multipotent Stem Cell.

Authors:  Shaghayegh Harbi; Rong Wang; Michael Gregory; Nicole Hanson; Keith Kobylarz; Kamilah Ryan; Yan Deng; Peter Lopez; Luis Chiriboga; Paolo Mignatti
Journal:  Sci Rep       Date:  2016-10-27       Impact factor: 4.379

7.  Gene expression analysis reveals marked differences in the transcriptome of infantile hemangioma endothelial cells compared to normal dermal microvascular endothelial cells.

Authors:  Jessica M Stiles; Rebecca K Rowntree; Clarissa Amaya; Dolores Diaz; Victor Kokta; Dianne C Mitchell; Brad A Bryan
Journal:  Vasc Cell       Date:  2013-03-25

8.  Mechanisms of propranolol action in infantile hemangioma.

Authors:  Jina Jy Kum; Zia A Khan
Journal:  Dermatoendocrinol       Date:  2015-01-26

9.  Identification of serum regression signs in infantile hemangioma.

Authors:  Daniela D'Arcangelo; Ezio M Nicodemi; Stefania Rossi; Claudia Giampietri; Francesco Facchiano; Antonio Facchiano
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

10.  Propranolol inhibits growth of hemangioma-initiating cells but does not induce apoptosis.

Authors:  Jina J Y Kum; Zia A Khan
Journal:  Pediatr Res       Date:  2013-12-02       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.